[Summary] Mainly engaged in the research and development, production of cell the
Wuxi Shengji Pharmaceutical Technology Co., Ltd. (referred to as "Shengji Pharmaceutical") was established in September 2017 in the Life Science Park, Huishan District, Wuxi City, Jiangsu Province. The company's core mission is to empower the cell and gene therapy industry, focusing on providing full-process services including the research and development, production, and registration application of high-quality cell and gene therapy products.
As a global CDMO service provider for cell and gene therapy, Shengji Pharmaceutical is committed to accelerating and innovating the research and development, production, and commercialization processes of cell and gene therapy and other advanced therapies, and has accumulated rich research and development and production experience in different product types such as plasmids, various viral vectors, and cell therapies. Relying on the deep technical accumulation, resource advantages, and service experience in this field, the company has built a "one-stop" service platform integrating research and development, production, and domestic and international registration of commercial products, providing global customers with high-quality, integrated, and professional outsourcing services from process development to commercial production, and facilitating the standardization and regularization of China's cell and gene therapy industry.
The company has established plant facilities, operating systems, and quality supervision systems fully compliant with Chinese, EU, and US GMP standards, and can tailor process development and production strategies, testing plans, and quality standards according to customer product characteristics, quality requirements, and research and development stages, while providing supporting regulatory consulting and registration application services.
To date, Shengji Pharmaceutical has obtained 23 clinical trial approvals and 2 clinical-stage change approvals covering countries and regions including China, the United States, Singapore, South Korea, Australia, and Germany; 6 customer projects have entered late stages and are advancing or preparing for PPQ validation; 1 project has submitted a marketing authorization application and is under review; 1 project has obtained marketing authorization in Mainland China, Macau, and Saudi Arabia, and marketing applications in Hong Kong and Singapore are in progress. In terms of the compliance system, following its first successful passing of the China NMPA registration on-site inspection in 2023, the company has smoothly passed 4 inspections by domestic drug regulatory authorities at various levels; in 2025, it completed an FDA on-site inspection and has cumulatively passed 3 EU QP inspections, fully demonstrating that the company has a quality supervision system and process research and development and production capabilities that can support global commercial drug production.
What does Wuxi Shengji Pharmaceutical Technology Co., Ltd. require? Who is Shengji Pharmaceutical hiring? Shengji Pharmaceutical recruitment: Factory Production占比最多占40%,其次是Biology/Pharmaceutical/Chemical/Environmental Protection占38%. What education can get in at Shengji Pharmaceutical? 本科占比最多占62%,其次是大专占14%. High education required at Shengji Pharmaceutical? 硕士占12%,博士占12%. Work experience required at Shengji Pharmaceutical? 3-5年占比最多占36%,其次是5-10年占30%. Where are the job locations at Shengji Pharmaceutical? 无锡占比最多占100%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows